search
programmed cell death
Trends
- 1
Artiva Biotherapeutics is discontinuing its cell therapy program after two patient deaths in trials, Reuters reports. The company will also cut its workforce by 94%, a drastic downsizing that effectively winds down its main pipeline. The deaths and near-total staff reduction make the survival of the clinical-stage biotech highly uncertain.
- 2
The Scientist is examining PCD — programmed cell death — in the context of the ongoing controversy over Nikon's AI-related claims. The piece asks what PCD actually looks like in practice, aiming to move past the dispute and focus on the underlying cell biology. It reflects broader scrutiny of how AI tools and their marketing claims are being applied in scientific imaging and research.
- 3Artiva to shut down after two trial deaths●After two deaths in autoimmune cell therapy trial, Artiva is shutting down
Biotech company Artiva Biotherapeutics is shutting down following the deaths of two patients enrolled in its cell therapy trial for autoimmune disease. The deaths prompted a halt to the study, leaving the company unable to continue operations. The case has revived debate over safety monitoring in cell therapy trials and the financial fragility of small biotechs whose fortunes hinge on a single clinical program.